Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × INDUSTRY × EP-100 membrane-disrupting peptide × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Cancer Recurrent 1

Interventions

Paclitaxel 239 Carboplatin 239 Gemcitabine 214 Bevacizumab 205 Cisplatin 200 Docetaxel 196 pembrolizumab 188 Pemetrexed 137 Capecitabine 131 Fluorouracil 115 Oxaliplatin 108 Cyclophosphamide 107 Nivolumab 96 Dexamethasone 85 Leucovorin 80 Trastuzumab 76 Rituximab 74 Irinotecan 74 Injections 68 Cetuximab 68 Prednisone 61 Erlotinib Hydrochloride 60 Ipilimumab 59 Doxorubicin 59 atezolizumab 58 Temozolomide 58 Bortezomib 57 Radiotherapy 52 Fulvestrant 50 Drug Therapy 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01485848 2014-06-10

ESP2011-002

Esperance Pharmaceuticals Inc

Phase 2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡